Corcept Therapeutics’ chief development officer sells $77,639 in stock

William Guyer, Chief Development Officer at Corcept Therapeutics Inc (NASDAQ:CORT), recently engaged in notable stock transactions. On April 1, Guyer sold 678 shares of Corcept Therapeutics’ common stock, generating approximately $77,639. The shares were sold at a weighted average price of $114.51, with sale prices ranging from $114.29 to $114.71 per share. The transaction comes as Corcept, currently valued at $8.86 billion, has delivered remarkable returns with the stock up 226% over the past year. According to InvestingPro analysis, the company maintains a GREAT financial health score of 3.47/5.

In addition to the sale, Guyer exercised stock options to acquire 678 shares at a price of $21.65 each, totaling $14,678. These transactions were conducted under a pre-established 10b5-1 trading plan adopted in November 2024. Following these transactions, Guyer holds 5,487 shares of Corcept Therapeutics’ common stock. The company boasts an impressive 98.39% gross profit margin and operates with minimal debt. Want deeper insights into insider trading patterns and comprehensive financial analysis? Access the full CORT Research Report on InvestingPro.

In other recent news, Corcept Therapeutics has announced positive results from its pivotal Phase 3 ROSELLA trial, which evaluated relacorilant combined with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The trial met its primary endpoint, showing improved progression-free survival and overall survival, with a 30% reduction in the risk of disease progression. Following these results, Corcept plans to submit a New Drug Application in the third quarter of 2025, targeting potential approval and market launch around 2026/27. Analysts from Truist Securities and H.C. Wainwright have both raised their price targets for Corcept to $150, maintaining Buy ratings on the stock. The analysts highlighted the favorable comparison of relacorilant’s performance against AbbVie (NYSE:ABBV)’s Elahere, which is currently approved for FRα-positive platinum-resistant ovarian cancer. In another development, the FDA has accepted Corcept’s New Drug Application for relacorilant for the treatment of Cushing’s syndrome, setting a Prescription Drug User Fee Act target action date of December 30, 2025. The company’s Chief Development Officer expressed optimism about relacorilant’s potential to establish a new standard of care for ovarian cancer, while the CEO highlighted its promise for Cushing’s syndrome. Relacorilant has also been granted orphan drug designation in both the United States and the European Union for these conditions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.